How does gene expression affect survival in early-stage lung adenocarcinoma?

In early-stage lung adenocarcinoma, patients with similar tumor stage can have very different outcomes. Gene expression — the activity levels of thousands of genes within the tumor and its surrounding environment — helps explain this variation. Specific patterns of gene activity can indicate whether a tumor is more likely to recur or lead to shorter survival. Research has identified several gene expression signatures that independently predict prognosis, offering potential tools for better risk stratification and treatment decisions.

What the research says

A 2024 study analyzing gene expression data from 292 early-stage lung adenocarcinoma patients found that certain coordinated gene programs are linked to recurrence risk. Programs enriched for B-cell and antibody responses, vascular homeostasis, and regulation of fibrotic remodeling were associated with reduced recurrence, while those involving epithelial organization and extracellular matrix remodeling conferred increased risk. These findings were validated in an independent cohort of 90 patients from TCGA, where pathway scores correlated with overall survival ⁵.

Another study developed a prognostic 8-gene signature (including ATAD5, CYP4F3, CYP4F12, ESPNL, FXYD2, GPX2, NLGN4Y, and SERPINC1) from tumor microenvironment-related genes. Patients with a high expression of this signature had worse overall survival. The signature was associated with altered immune cell infiltration, including fewer naïve B cells and plasma cells, and more M1 macrophages ¹⁰.

A large-scale analysis of 1,720 lung adenocarcinoma patients created an acylation modification score (AM.score) based on 12 types of gene modifications. This score outperformed standard prognostic indicators in predicting outcomes and was also validated across multiple independent cohorts and in immunotherapy response prediction ⁸.

Additionally, gene expression changes induced by cigarette smoking — particularly involving cell cycle genes like NEK2, TTK, and PRC1 — persist even after smoking cessation and are associated with worse survival in early-stage disease ⁹. Long non-coding RNAs (lncRNAs) also show differential expression that can promote or inhibit tumor progression, affecting patient prognosis ¹¹.

What to ask your doctor

• Could my tumor be tested for gene expression signatures that predict recurrence risk?
• What do the immune-related gene expression patterns in my tumor suggest about my prognosis?
• Are there any clinical trials using gene expression profiles to guide treatment decisions for early-stage lung adenocarcinoma?
• How might smoking-related gene expression changes affect my long-term outlook?
• Should I consider additional therapies based on the gene expression characteristics of my cancer?